Experimental drug targets deadly lung complication in rare autoimmune disease
NCT ID NCT07486869
First seen Mar 30, 2026 · Last updated May 05, 2026 · Updated 3 times
Summary
This early study tests whether emapalumab, a drug used for a severe immune overreaction, can help people with a rare, rapidly worsening lung disease linked to anti-MDA5 antibodies. The trial will enroll 5 adults whose lung function is declining despite standard care. The main goal is to see if the drug reduces oxygen needs and improves breathing tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami Hospital and Clinics
Miami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.